The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Putin’s ‘Fog of War’ missile confuses experts, but that’s his plan
next post
Stop funding the woke and the stupid

Related Posts

Israel strikes Hezbollah targets inside Lebanon; IDF warns...

September 20, 2024

US Embassy in Israel tells government employees, families...

June 15, 2025

Hegseth orders ‘historic’ reduction of general officers in...

May 6, 2025

Trump’s campaign rival decides between voting for him...

May 23, 2024

Barron Trump debuts at father’s Florida campaign rally...

July 11, 2024

Matt Gaetz resigns from Congress over Trump nod...

November 14, 2024

Could verdict in Trump criminal trial upend the...

May 30, 2024

Chicago Pro-Palestinian groups reject White House requests to...

March 16, 2024

DAVID MARCUS: Why Teamsters members think Trump, not...

September 19, 2024

Palestinian official predicts Trump will ‘destroy’ Iran, leading...

January 1, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Apple reveals complex system of App Store fees to avoid E.U. fine of 500 million euros

      June 30, 2025
    • Breakdown of NVDA’s Stock Price and S&P 500: Actionable Technical Insights

      June 30, 2025
    • Thom Tillis announces retirement from Senate after clash with Trump

      June 30, 2025
    • SCOOP: House Republican eyes bid for Thom Tillis Senate seat after Trump attack

      June 30, 2025
    • Dem delay tactic ends, debate begins on Trump’s ‘big, beautiful bill’

      June 30, 2025
    • GOP, Dem senators remain divided over Medicaid after Trump’s ‘big, beautiful bill’ vote

      June 30, 2025

    Categories

    • Business (1,272)
    • Politics (3,873)
    • Stocks (1,477)
    • Uncategorized (45)
    • World News (1,265)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved